CH BIOTECH SER(08037.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
CH BIOTECH SER
08037.HK
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People’s Republic of China and Hong Kong. The company operates through Medical and Health Related Services, Immunotherapy, Pharmaceutical Products, Insurance Brokerage, BNCT, and Others segments. It also engages in the provision of tumor immune cell therapy and health management services; sale and distribution of health related and pharmaceutical products; insurance brokerage services; provision of boron neutron capture therapy treatment services; provision of logistic services; and property investment activities. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017.
55.92 B
08037.HKMarket value -Rank by Market Cap -/-

Financial Score

21/05/2026 Update
D
Health Care ServicesIndustry
Industry Ranking25/31
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-30.14%E
    • Profit Margin-93.57%E
    • Gross Margin10.51%E
  • Growth ScoreC
    • Revenue YoY4.25%C
    • Net Profit YoY65.29%B
    • Total Assets YoY32.57%A
    • Net Assets YoY-35.75%E
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY4.25%C
  • Operating ScoreE
    • Turnover0.12E
  • Debt ScoreE
    • Gearing Ratio77.83%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck

    Tip Ranks·
    HK
    01177
    +1.93%
    HK
    08037
    0.00%
    SH
    512010
    +1.73%
    Tip Ranks·
    HK
    01177
    +1.93%
    HK
    08037
    0.00%
    SH
    512010
    +1.73%

    Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM

    Wallstreetcn·
    SH
    516820
    +0.91%
    SZ
    159929
    +1.76%
    SZ
    159506
    +1.59%
    Wallstreetcn·
    SH
    516820
    +0.91%
    SZ
    159929
    +1.76%
    SZ
    159506
    +1.59%

    Heilongjiang: Encouraging leading enterprises in biomanufacturing to take the lead in forming industry technology innovation alliances, industry technology research institutes, and other innovation consortia

    Wallstreetcn·
    SH
    560600
    0.00%
    SZ
    159849
    +1.47%
    SH
    588250
    +3.30%
    Wallstreetcn·
    SH
    560600
    0.00%
    SZ
    159849
    +1.47%
    SH
    588250
    +3.30%

    The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

    Wallstreetcn·
    HK
    01093
    -1.08%
    HK
    01801
    +2.83%
    HK
    02269
    -0.12%
    Wallstreetcn·
    HK
    01093
    -1.08%
    HK
    01801
    +2.83%
    HK
    02269
    -0.12%

    CH BIOTECH SER's subsidiary has been granted a loan with a principal amount of up to 180 million yuan

    Zhitong·
    HK
    08037
    0.00%
    Zhitong·
    HK
    08037
    0.00%
    © 2026 Longbridge｜Disclaimer